84-LB: HbA1c Reduction after Initiation of the FreeStyle Libre System in Type 2 Diabetes Patients on Long-Acting Insulin or Noninsulin Therapy
The DOI matches its Crossref record.
Abstract
Data for patients with type 2 diabetes (T2D) on long-acting insulin (LAI) or non-insulin therapy using continuous glucose monitors is limited. This study evaluates change in HbA1c from baseline to 6mo and baseline to 12mo after starting a FreeStyle Libre system for T2D patients on LAI and non-insulin (including GLP-1) therapy. A retrospective, observational analysis was performed by linking data from the LibreView® data management platform, DRG (a commercial medical and pharmacy claims database), and Quest lab HbA1c. Only deidentified data was used for analysis. Index was the first date of data in LibreView (Nov 2017-Sept 2019). Medication and diagnosis were from DRG. HbA1c tests were from Quest. Baseline A1c must be ≥ 6.5% within 6mo prior to index. HbA1c tests closest to +180 days (+150-210) used for 6mo; closest to +360 days (+330-390) used for 12mo. The 6mo T2D cohort (n=774) reduced HbA1c by -0.8%. The 12mo T2D cohort (n=207) reduced HbA1c by -0.6%. The greatest reduction in HbA1c was seen in the T2D non-insulin group at 6mo (-0.9%, n=497) and 12mo (-0.7% n=120). All groups saw clinically significant reduction in HbA1c (Table). Reduction in HbA1c post-FreeStyle Libre use supports the real-world effectiveness of the system in T2D patients using long-acting insulin or non-insulin therapies. Disclosure: E. Miller: None. L. Brandner: Employee; Self; Abbott Laboratories. E. Wright: Advisory Panel; Self; Abbott, Sanofi. Consultant; Self; Abbott, AstraZeneca, Bayer U.S., Boehringer Ingelheim Pharmaceuticals, Inc., MannKind Corporation, Merck & Co., Inc., Voluntis France. Speaker’s Bureau; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Lilly Diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among the noninsulin therapy users, they observed HbA1c reductions of 0.9% (n = 497; p < 0.0001) and 0.7% (n = 120; p < 0.0001) at 6 and 12 months, respectively, with a mean baseline HbA1c of 8.5%–8.6%.”
Citations
Cites
Still being checked.
Cited by
Continuous glucose monitoring: The achievement of 100 years of innovation in diabetes technology
Galindo, R. J., & Aleppo, G. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108502 · Cited by 133
A review of flash glucose monitoring in type 2 diabetes
Krakauer, M., Botero, J. F., Lavalle-González, F. J., Proietti, A., & Barbieri, D. E. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00654-3 · Cited by 71
Carlson, A. L., Daniel, T. D., DeSantis, A., Jabbour, S., Karslioglu French, E., Kruger, D., Miller, E., Ozer, K., & Elliott, T. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002590 · Cited by 69
Self-citationElliott, T., Beca, S., Beharry, R., Tsoukas, M. A., Zarruk, A., & Abitbol, A. (2021) · Diabetes and Vascular Disease Research · doi:10.1177/14791641211021374 · Cited by 49
Galindo, R. J., Parkin, C. G., Aleppo, G., Carlson, A. L., Kruger, D. F., Levy, C. J., Umpierrez, G. E., & McGill, J. B. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0107 · Cited by 38
Metadata
- Authors
- MILLER, E., BRANDNER, L., & WRIGHT, E.
- Affiliations
- Bend, OR, Alameda, CA, Charlotte, NC
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2020-06-01
- Volume
- 69
- Issue
- Supplement_1
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W3035393026
- Cited by
- 23
- References
- 0
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 1 · 2023: 1 · 2022: 3 · 2021: 10 · 2020: 2
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- type 2 diabetes, HbA1c reduction, FreeStyle Libre, continuous glucose monitoring, long-acting insulin, non-insulin therapy, GLP-1 receptor agonists, glycemic control, real-world effectiveness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 84-LB: HbA1c Reduction after Initiation of the FreeStyle Libre System in Type 2 Diabetes Patients on Long-Acting Insulin or Noninsulin Therapy. https://app.cochat.ai/papers/10.2337/db20-84-lb
- The paper
- MILLER, E., BRANDNER, L., & WRIGHT, E. (2020). 84-LB: HbA1c Reduction after Initiation of the FreeStyle Libre System in Type 2 Diabetes Patients on Long-Acting Insulin or Noninsulin Therapy. Diabetes. https://doi.org/10.2337/db20-84-lb
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.